General Information of Drug (ID: DMYK6OU)

Drug Name
RQ-00310941 Drug Info
Synonyms RQ-00202065; 5-HT 2b antagonists (oral, IBS), RaQualia; 5-HT 2b antagonists (oral, irritable bowel syndrome), RaQualia
Indication
Disease Entry ICD 11 Status REF
Irritable bowel syndrome DD91.0 Investigative [1]
Cross-matching ID
PubChem CID
46208154
TTD Drug ID
DMYK6OU

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug(s) Targeting 5-HT 2B receptor (HTR2B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [2]
Triflupromazine DMKFQJP Nausea MD90 Approved [3]
Minaprine DM0EP7M Depression 6A70-6A7Z Approved [4]
SPN-812 DMTV7XH Attention deficit hyperactivity disorder 6A05.Z Phase 4 [5]
Vabicaserin DM9GZW6 Psychotic disorder 6A20-6A25 Phase 2 [6]
PRX-08066 DMR7H2V Pulmonary arterial hypertension BB01.0 Phase 2 [7]
Pyrimidine derivative 29 DMVOYJ8 N. A. N. A. Patented [8]
Pyrimidine derivative 26 DM90WKN N. A. N. A. Patented [8]
Pyrimidine derivative 23 DM5MLQU N. A. N. A. Patented [8]
Pyrimidine derivative 25 DM51MFS N. A. N. A. Patented [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 2B receptor (HTR2B) TT0K1SC 5HT2B_HUMAN Antagonist [1]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 7).
2 Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
3 Some properties of 5-hydroxytryptamine receptors in the hindquarters of the rat. Br J Pharmacol. 1979 Sep;67(1):79-85.
4 Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
5 New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300.
6 Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.
7 Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
8 Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.